GT Biopharma (GTBP) Operating Leases (2022 - 2024)

GT Biopharma (GTBP) has reported Operating Leases for 3 consecutive years, with $30000.0 the latest figure, recorded in Q1 2024.

• On a quarterly basis, Operating Leases fell 3.23% year-over-year to $30000.0 in Q1 2024; TTM through Mar 2024 was $30000.0, a 3.23% decrease from a year earlier, with the FY2023 full-year figure at $58.0 million, up 90525.0% from the prior year.
• Operating Leases was $30000.0 for Q1 2024 at GT Biopharma, down from $58.0 million in the prior quarter.
• Over five years, Operating Leases peaked at $58.0 million in Q4 2023 and troughed at $30000.0 in Q1 2024.
• A 3-year average of $8.4 million and a median of $92000.0 in 2022 frame the typical range for Operating Leases.
• The widest YoY moves for Operating Leases: up 90525.0% in 2023, down 78.91% in 2023.
• Over 3 years, Operating Leases stood at $64000.0 in 2022, then jumped by 90525.0% to $58.0 million in 2023, then plunged by 99.95% to $30000.0 in 2024.
• The last three Operating Leases figures came in at $30000.0 (Q1 2024), $58.0 million (Q4 2023), and $31000.0 (Q1 2023), per Business Quant data.